Hydroxymethyl-Glutaryl Coenzyme A Reductase Inhibition Limits Cytomegalovirus Infection in Human Endothelial Cells

Circulation

Volumn 109, Issue 4, 2004, Pages 532-536

  Potena, Luciano ^a   Frascaroli, Giada ^a,b   Grigioni, Francesco ^a   Lazzarotto, Tiziana ^a   Magnani, Gaia ^a   Tomasi, Luciana ^a   Coccolo, Fabio ^a   Gabrielli, Liliana ^a   Magelli, Carlo ^a,c   Landini, Maria P ^a   Branzi, Angelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c Institute of Cardiology   (Italy)

Author keywords

Atherosclerosis; Endothelium; Infection; Statins; Viruses

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEVALONIC ACID; VIRUS ANTIGEN; VIRUS DNA;

ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BINDING KINETICS; CHOLESTEROL METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DNA DETERMINATION; DNA SYNTHESIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INCUBATION TIME; INFECTION COMPLICATION; INHIBITION KINETICS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ASSAY; STATISTICAL ANALYSIS; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIGENS, VIRAL; CELLS, CULTURED; CYTOMEGALOVIRUS; DNA, VIRAL; ENDOTHELIUM, VASCULAR; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; NF-KAPPA B; VIRION;

EID: 10744224261     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000109485.79183.81     Document Type: Article

References (26)

1. Ross P. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413-428.
3. Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:58-63.
4. Epstein S, Zhu J, Burnett M, et al. Infection and atherosclerosis: potential role of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol. 2000;20:1417-1420.
5. Levi M. CMV endotheliitis as a factor in the pathogenesis of atherosclerosis. Cardiovasc Res. 2001;50:432-433.
6. Espinola-Klein C, Rupprecht H, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 2002;105:15-21.
7. Potena L, Grigioni F, Ortolani P, et al. Relevance of cytomegalovirus infection and coronary artery remodeling in the first year after transplantation. Transplantation. 2003;75:839-843.
8. Valantine H, Gao S, Menon S, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation. 1999;100:61-66.
9. Fishman J, Rubin H. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741-1751.
10. Jaffe E, Nachman R, Becker C, et al. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
11. Lopez S, Peiretti F, Bonardo B, et al. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis. 2000;152:359-366.
12. Sporri S, Chopra V, Egger N, et al. Effects of 5-aminolaevulinic acid on human ovarian cancer cells and human vascular endothelial cells in vitro. J Photochem Photobiol. 2001;64:8-20.
13. Riegler S, Hebart H, Einsele H, et al. Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J Gen Virol. 2000;81(pt 2):393-399.
14. Gleaves C, Smith T, Shuster E, et al. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol. 1984;19:917-919.
15. Lazzarotto T, Varani S, Guerra B, et al. Prenatal indications of congenital cytomegalovirus infection. J Paediatr. 2000;137:90-95.
16. Schmid R, Liptay S, Betts J, et al. Structural and functional analysis of NF-κB. J Biol Chem. 1994;51:32162-32167.
17. Wahl C, Lyptay S, Adler G, et al. Sulfalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998;101:1163-1174.
18. Kowalik T, Wing B, Haskill J, et al. Multiple mechanisms are implicated in the regulation of NF-κB activity during human cytomegalovirus infection. Proc Natl Acad Sci U S A. 1992;90:1107-1111.
19. Speir E, Yu Z, Ferrans V, et al. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ Res. 1998;83:210-216.
20. Kahl M, Siegel-Axel D, Stengelein S, et al. Efficient lytic infection of human arterial endothelial cells by human cytomegalovirus strains. J Virol. 2000;74:7628-7635.
21. Bustos C, Hernandez-Presa M, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057-2064.
22. Ortego M, Bustos C, Hernàndez-Presa M, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147:253-261.
23. Barnes P, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
24. Dechend R, Gieffers J, Dietz R, et al. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation 2003;108:261-265.
25. Overmeyer JH, Maltese WA. Isoprenoid requirement for intracellular transport and processing of murine leukemia virus envelope protein. J Biol Chem. 1992;267:22686-22692.
26. Horne B, Muhlestein J, Carlquist J, et al. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation. 2003;107:258-263.